The company's 2012-2014 EPS is expected to be 0.69, 0.81, and 0.94 yuan, respectively. Currently, the average dynamic price-earnings ratio of comparable companies in 2012 is 29 times; considering the current situation where the growth rate has slowed in the past two years due to the company's production capacity restrictions, we believe that using an appropriate discount compared to the industry average better reflects the current reasonable value of the company. Thus, according to the 2012 dynamic valuation range of 21-23 times PE, the company's reasonable value range is 14.5-15.9 yuan.
【渤海证券】双成药业新股询价报告:多肽行业领军者蓄势待发
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.